Viatris Inc - Company Profile
Powered by 
All the sales intelligence you need on Viatris Inc in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Viatris Inc fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Viatris Inc.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Viatris Inc (Viatris) is a pharmaceutical company. It offers oral solid doses (OSD), injectables, complex dosage forms, and APIs in therapeutic areas of cardiovascular, CNS and anesthesia, dermatology, diabetes and metabolism, eye care, gastroenterology, immunology, infectious disease, oncology, respiratory and allergy, and women's healthcare. Viatris products are offered to patients, hospitals, nursing homes, and clinics through pharmaceutical wholesalers, distributors, and retailers; institutional pharmacies; mail-order and e-commerce pharmacies; and specialty pharmacies in the Americas, Europe, Asia, Africa, and the Middle East. The company operates its manufacturing and packing facilities in Australia, Egypt, France, Germany, Greater China, Hungary, India, Ireland, South Africa, Turkey, the US, and Zambia. Viatris is headquartered in Canonsburg, Pennsylvania, the US.
Headquarters
United States of America
Address
1000 Mylan Boulevard, Canonsburg, Pennsylvania, 15317
Website
www.viatris.com
Telephone
1 724 5141800
No of Employees
30,000
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
VTRS (NASD)
Revenue (2024)
$14.3B
-3%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
-454.2%
(2024 vs 2023)
Market Cap*
$19.6B
Net Profit Margin (2024)
XYZ
-471.6%
(2024 vs 2023)
* As of and is in US$
Viatris Inc premium industry data and analytics
Products and Services
| Products | Services | Brands |
|---|---|---|
| Oral Solid Doses (OSD) | Support | Lipitor |
| Injectables | Diagnostic Clinics | Norvasc |
| Complex Dosage Forms | Educational Seminars | Caduet |
| XYZ | XYZ | XYZ |
| XYZ | XYZ | XYZ |
| XYZ | XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2026 | Regulatory Approval | In September, the company secured approval from the Ministry of Health, Labour and Welfare for WAKIX (pitolisant) to treat patients with excessive daytime sleepiness (EDS) associated with obstructive sleep apnea syndrome. |
| 2026 | Regulatory Approval | In September, Viatris Pharmaceuticals LLC received approval for two indications for its histamine H3 receptor antagonist/inverse agonist, Uekix Tablets 5mg/20mg: narcolepsy and excessive daytime sleepiness associated with obstructive sleep apnea syndrome in patients. |
| 2026 | Contracts/Agreements | In August, the company entered into an agreement to sell TYRVAYA to Harrow, a provider of ophthalmic disease management solutions. |
Competitor Comparison
| Key Parameters | Viatris Inc | Merck & Co Inc | GSK plc | Teva Pharmaceutical Industries Ltd | Sandoz Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United Kingdom | Israel | United States of America |
| City | Canonsburg | Rahway | London | Tel Aviv | Princeton |
| State/Province | Pennsylvania | New Jersey | England | Tel Aviv | New Jersey |
| No. of Employees | 30,000 | 75,000 | 66,841 | 31,173 | - |
| Entity Type | Public | Public | Public | Public | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Scott A. Smith | Director; Chief Executive Officer | Executive Board | 2023 | 63 |
| Hemanth J. Varghese | Chief Strategy Officer | Senior Management | 2025 | - |
| Ramkumar Rayapureddy | Chief Information Officer | Senior Management | 2016 | - |
| Matthew J. Maletta | Chief Legal Officer | Senior Management | 2026 | 54 |
| Andrew Enrietti | Chief Administrative and Transformation Officer | Senior Management | 2025 | 42 |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer